Zymeworks Inc. (ZYME) EPS Estimated At $-0.62; Shorts at Cbtx (CBTX) Raised By 113.55%

January 14, 2018 - By Hazel Jackson

Analysts expect Zymeworks Inc. (NYSE:ZYME) to report $-0.62 EPS on February, 14.After having $-0.65 EPS previously, Zymeworks Inc.’s analysts see -4.62% EPS growth. The stock increased 0.02% or $0.0015 during the last trading session, reaching $9.4915. About 15,081 shares traded. Zymeworks Inc. (NYSE:ZYME) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Cbtx Incorporated (NASDAQ:CBTX) had an increase of 113.55% in short interest. CBTX’s SI was 78,800 shares in January as released by FINRA. Its up 113.55% from 36,900 shares previously. With 32,900 avg volume, 2 days are for Cbtx Incorporated (NASDAQ:CBTX)’s short sellers to cover CBTX’s short positions. The stock increased 0.33% or $0.1 during the last trading session, reaching $30. About 34,773 shares traded. CBTX, Inc. (NASDAQ:CBTX) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

CBTX, Inc. operates as the bank holding firm for CommunityBank of Texas, N.A. that provides commercial banking solutions to small and mid-sized businesses, and professionals in Houston and Beaumont, Texas. The company has market cap of $751.37 million. The company??s deposit products include checking and savings accounts, certificates of deposit, and money market accounts; and loan portfolio comprises consumer loans, including residential real estate loans, home equity loans, home equity lines of credit, installment loans, unsecured and secured personal lines of credit, overdraft protection, and letters of credit. It has a 20 P/E ratio. It also provides commercial and industrial loans, commercial real estate-backed loans, commercial lines of credit, working capital loans, term loans, equipment financing, borrowing base loans, construction and development loans, homebuilder loans, agricultural loans, small business administration loans, and other loan products, as well as acquisition, expansion, and development loans.

Among 4 analysts covering Zymeworks (NYSE:ZYME), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zymeworks had 4 analyst reports since May 23, 2017 according to SRatingsIntel. Canaccord Genuity initiated the shares of ZYME in report on Tuesday, May 23 with “Buy” rating. The firm has “Outperform” rating by Wells Fargo given on Tuesday, May 23. Barclays Capital initiated it with “Overweight” rating and $20 target in Tuesday, May 23 report. The stock has “Buy” rating by Citigroup on Tuesday, May 23.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company has market cap of $238.99 million. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It currently has negative earnings. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: